|Articles|March 15, 2002
Therapeutic index 'low': AMD treatment feasible, but Santen pulls out
Salt Lake City-IOMED Inc. and Santen Pharmaceuticals Co. said they have ended a joint development agreement intended to launch a noninvasive ophthalmic drug delivery system to provide an anti-angiogenic drug to the retina and choroid in therapeutic quantities.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
AAO 2025 Takeaways: Cornea, refractive surgery, and aesthetics redefined
2
AAO 2025 Takeaways: The new era of glaucoma treatment and surgical precision
3
AAO 2025 Takeaways: The next frontier in retinal therapeutics arrives
4
Ocular Therapeutix randomizes first patient in HELIOS-3
5













































.png)


